Currently, the NCCN guidelines for pancreatic cancer have no guidance for individualized chemotherapy, save for a recommendation that patients with germline BRCA1/2 gene mutations choose platinum chemotherapy. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.